Akbari Dr. Homaira 4

What Happened
Dr. Homaira Akbari, a director of Babcock & Wilcox Enterprises (BW), exercised/converted derivative rights for 3,021 shares on May 15, 2026, paying $21.22 per share for a total cash outlay of $64,106. The filing also shows grants/awards of contingent rights totaling 11,746 shares: 3,021 granted on Jan 29, 2026 and 8,725 granted on May 15, 2026. The exercise resulted in acquisition of 3,021 common shares; a corresponding "disposed" derivative entry for 3,021 at $0.00 reflects conversion/cancellation of the derivative instrument upon exercise.

Key Details

• Transactions reported:
  • 2026-05-15: Exercise/conversion (M) — acquired 3,021 shares @ $21.22 ($64,106 total).
  • 2026-05-15: Disposed 3,021 derivative units @ $0.00 (represents conversion of the derivative).
  • 2026-01-29: Grant/award (A) — 3,021 derivative units @ $0.00.
  • 2026-05-15: Grant/award (A) — 8,725 derivative units @ $0.00.
• Shares owned after the transactions: not specified in the filing.
• Footnotes of note:
  • F1: Some awards vest May 15, 2026 or at next Annual Meeting, whichever is earlier.
  • F2: Awards are contingent rights under the 2021 Long‑Term Incentive Plan; each right represents a contingent claim to one share.
  • F3: Some awards vest May 15, 2027 or at next Annual Meeting, whichever is earlier.
• Filing/timeliness: Form filed 2026-05-19. Form 4s are generally due within two business days of a transaction; the May 15 transactions were reported on May 19 (four calendar days later), which may indicate a delayed filing.

Context

• This was an exercise/conversion of derivative rights (not an open‑market purchase or sale). The director paid the exercise price to receive shares rather than immediately selling them, so this is an acquisition of stock rather than a cashless sale.
• The awarded/contingent units are subject to vesting schedules and represent future rights to receive shares if vesting conditions are met; such awards do not necessarily signal immediate insider sentiment.
• As always, filings by corporate insiders are factual records of transactions — they do not state the insider’s motives.